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ABSTRACT 
Objective: The main objective of this study was to investigate the in vitro metabolic profile of etodolac (ETD) using normal human hepatic cell lines 
and chicken liver tissue, and to characterize the metabolites obtained using Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS).  
Methods: In the present study, the metabolic profile of ETD, a well-known non-steroidal anti-inflammatory drug (NSAID), was investigated in 
normal human hepatic cell lines and chicken liver tissue employing LC-MS/MS technique. The structural details on ETD metabolites were acquired 
using triple quadrupole mass spectrometer (LCMS-8040, Shimadzu). The metabolites were produced by incubation of ETD with the human hepatic 
cell lines and chicken liver tissue, at 37 °C for 24 h. The incubated extracts were analyzed with LC-MS/MS and their production spectra were 
acquired, interpreted and tentative structures were proposed. 
Results: Six phase I and phase II metabolites were successfully detected in the proposed study. The metabolic changes observed included-oxidation, 
N-acetylation, hydrogenation, decarboxylation, methylation and glucuronidation of dehydrogenated ETD. The tentative structures of the 
metabolites were postulated based on the chemical reactions predicted and the LC-MS/MS data obtained.  
Conclusion: The in vitro metabolites of ETD were successfully investigated and characterized in human hepatic cell lines and chicken liver tissue. 
Also, both the models were found to be equally effective for carrying out the in vitro metabolic study of ETD. 
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INTRODUCTION 
ETD (fig. 1), (RS)-2-(1, 8-Diethyl-4, 9-dihydro-3H-pyrano [3, 4-b] 
indol-1-yl) acetic acid is a well-known member of the pyrano-
carboxylic acid group of NSAID, approved by the U. S. Food and Drug 
Administration (FDA). This group of drugs has anti-inflammatory, 
analgesic and antipyretic activities. ETD is used worldwide to relieve 
inflammation, swelling, stiffness and joint pain in conditions like 
osteoarthritis, rheumatoid arthritis, and postoperative pain, as well 
as for general pain relief. Their pharmacological actions are related 
to inhibition of prostaglandin biosynthesis at the site of 
inflammation [1, 2]. ETD is extensively metabolized in the liver. 
Renal elimination of ETD mainly as glucuronide and its other phase I 
and phase II metabolites is the primary route of excretion [3].  
Metabolism is a pr°Cess of biotransformation where drugs are 
transformed into a different chemical form by enzymatic reactions. 
Metabolism mainly increases drug hydrophilicity and decreases the 
toxicity and activity of most drugs. The study of the metabolic fate of 
drugs (absorption, distribution, metabolism, excretion and 
toxicology) is an essential and important part of the drug discovery 
development pr °Cess. Data on metabolism are used to optimize 
drug candidates, namely to suggest more active compounds or 
support further toxicology studies. Biotransformation may °Ccur in 
liver, intestine, kidney, lungs, brain, nasal epithelium and skin. But, 
liver is by far, the most important organ for drug metabolism [4].  
Drugs are metabolized by different reactions that are classified into 
two groups: phase I and phase II. Phase I reactions mostly include 
oxidation, reduction, and hydrolysis. The function of phase I 
reactions is to introduce a new functional group within a molecule, 
to modify an existing functional group or to expose a functional 
group that is a substrate for phase II reactions. Phase I reactions are 
responsible for the enhancement of drugs’ hydrophilicity. Phase II 
reactions represent conjugating reactions and mainly further 
increase the hydrophilicity and facilitate the excretion of 
metabolites from the body [5].  
The analysis of metabolites in complex biological matrices is a 
challenging task, therefore, several analytical methods for 
qualification and quantification of drug metabolites are used. Liquid 
chromatography coupled with mass spectrometry (LC-MS) has 
become the most powerful analytical tool for screening and 
identification of drug metabolites in biological matrices due to its 
selectivity, sensitivity and speed of analysis. The LC-MS/MS methods 
are considered as most appropriate for the determination of drugs 
and their metabolites and are also best suited for high throughput 
analysis. Crude extracts of in vitro incubation and in vivo samples 
can be subjected to metabolite profiling and identification by LC-
MS/MS. Complex metabolite mixtures are resolved chromate-
graphically on a high-performance liquid chromatography (HPLC) 
column and full scan MS and production scan MS/MS data are 
generated on-line. Thus, the molecular weight of drug metabolites 
and l°Calization of the biotransformation sites can be elucidated 
based on interpretation of the MS/MS data [6]. 
The proposed study was carried out using normal human hepatic 
cell lines and chicken liver tissue. Liver cell lines are easy to culture 
and have stable enzyme concentration. These can be cultured in a 
monolayer in order to prolong the viability to four weeks. This 
characteristic in combination with the prolonged regulatory 
pathways allows the use of this in vitro model in studies of up-
regulation or down-regulation of metabolites. The major sources of 
cell lines are primary tumors of liver parenchyma. On the other 
hand, isolated liver also gives an excellent representation of the in 
vivo situation. The additional advantages of this in vitro model are 
three-dimensional architecture and presence of hepatic as well as 
non-hepatic cell types [7, 8]. Considering these advantages, the two 
models were selected for the proposed study, to determine and 
characterize the in vitro metabolites of ETD. 
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Several techniques have been reported in the literature for the 
analysis of ETD and its metabolites, of which HPLC-UV [9-14] is the 
most common technique. Other instruments such as gas 
chromatography with nitrogen phosphorous detection (GC-NPD) 
[15], electrophoresis [16, 17] and GC-MS [18] have also been used. 
Until now, the mono-hydroxylated metabolites of ETD, namely, 5-
hydroxy [3], 6-hydroxy, 7-hydroxy and 8-(1’-hydroxyethyl) ETD 
were identified and reported [19, 20]. Furthermore, the acyl 
glucuronides of the mono hydroxylated metabolites, as well as ETD 
glucuronide, were also reported [21, 22]. In addition to this, reports 
on the existence of 4-ureido etodolac were found in the literature 
[23]. However, the metabolites obtained in the present research work 
have not been reported in the literature as yet, to the best of our 
knowledge. Also, so far, no studies involving the investigation of ETD 
metabolites in the proposed two in vitro models have been conducted.  
Thus, the main aim of the present study was to investigate the in 
vitro metabolic profile of ETD in normal human hepatic cell lines and 
chicken liver tissue, using LC-MS/MS technique. Based on the MS 
and MS/MS data, the chemical structures for the metabolites were 
proposed and new in vitro metabolites of ETD which were not 
published as yet were presented. 
 
 
Fig. 1: Chemical structure of etodolac 
 
MATERIALS AND METHODS 
Chemicals and reagents 
ETD API was procured from Hetero Chemical Lab (Hyderabad, 
India) with a purity of 99.4 % w/w. 
HPLC grade acetonitrile (CH3CN), formic acid (HCOOH), water; 
analytical grade ethyl alcohol (C2H5OH), potassium Chloride (KCl), 
potassium diphosphate (KH2PO4), sodium chloride (NaCl), disodium 
phosphate (Na2HPO4), sodium hydroxide (NaOH), sodium lauryl 
sulfate (SLS) were purchased from Merck (Mumbai, India). 
Dulbecco’s modified eagle’s medium (DMEM) was purchased from 
Sigma-Aldrich (Mumbai, India), foetal calf Serum (FCS) from Biowest 
(Mumbai, India), Ttypsin-versene mixture from Himedia (Mumbai, 
India) and gentamycin from Nicholas Piramal (Mumbai, India). 
THLE-3 (ATCC-CRL-11233) normal human liver cell line was 
procured from ATCC. 
The fresh chicken liver was collected from the l°Cal butcher shop. 
Equipments 
Centrifuge (EMTEK), CO2 Incubator (Thermo Forma Series II), Epi-
Fluorescent Inverted Microscope (AXIOVERT S-100). 
From the literature, few similar research works were referred to 
carry out the present study [24, 25]. 
Stock preparation 
To get a final concentration of 400µg/ml for cell line study and 
1000µg/ml for liver tissue study, a parent stock of 10 mg/ml of ETD 
API was initially dissolved in minimum quantity of ethyl alcohol 
followed by the addition of DMEM. This was filter sterilized through 
0.22 µ membrane filter. This parent stock was further used to 
prepare concentrations of 4000 µg/ml and 10,000 µg/ml. From 
these stock solutions, 10 µl was added to 90 µl of cell suspension in 
96-well plate making the final concentrations of 400µg/ml and 
1000µg/ml for cell lines and chicken liver tissue respectively. 
Maintenance of cell line 
THLE-3 (ATCC-CRL-11233) normal human liver cell line was 
procured from ATCC. Cells were maintained at 37 °C in humid 
conditions (5 % CO2/95 % air) of CO2 incubator; suspended in 
DMEM supplemented with 10 % FCS. Cells were sub-cultured on 
every 4th day using 0.25 % trypsin-versene mixture for harvesting 
the cells, in order to confirm the normal growth pattern of the cells 
before using it for the experiment. 
In vitro experiment using liver cell line  
Exponentially growing cells in the flasks were harvested by 
trypsinization with 0.25 % trypsin-versene and suspended in DMEM 
medium supplemented with 10 % FCS. Cells with a density of 
1x103cells/well were seeded in 96 well plates and incubated at 37 °C 
in CO2 incubator for 24 h to allow them to adhere to the surface and 
form a monolayer. The medium was then aspirated carefully, and 
the cells were switched to DMEM medium consisting of required 
concentration of API without disturbing the adhered cells. The 
supernatant was aspirated and the cells were lysed using 100 µl of 
lysis buffer (1N NaOH solution with 0.5 % SLS) in each well. Lysis of 
the cells was facilitated by incubating the plates for 30 min at 37 °C. 
Later, appropriate cell lysates were collected and pooled together in 
a micr°Centrifuge tube, centrifuged at 1000 rpm for 3 min. The pellet 
was discarded and the supernatant was collected in a separate 
sterile micr°Centrifuge tube. To this acetonitrile was added in order 
to precipitate the proteins present. The extract was vertex and then 
centrifuged at 8000 rpm for 10 min. The pellet was discarded and 
the supernatant was filtered through 0.22 µ Millipore membrane 
filter and used for further analysis on LC-MS/MS. 
Blank was prepared in a similar fashion without spiking of the drug. 
Images of the cells of the blank as well as the test samples, during 
the incubation time, were taken from the inverted microscope and 
are shown in fig. 2. 
In vitro experiment using chicken liver tissue  
Fresh chicken liver was collected from the l°Cal butcher shop and 
cleaned with sterile phosphate buffered saline (PBS) to remove 
traces of blood and dust particles. The intact tissue was surface 
sterilized with absolute ethyl alcohol for 30 seconds and washed 
with sterile PBS to remove the traces of alcohol. The tissue was then 
aseptically sliced to approximately 7 mm X 7 mm pieces for the 
experiment. The tissue samples were suspended in DMEM medium 
supplemented with 10 % FCS in 24 well plates and incubated at 37 
°C in CO2 incubator for 24 h. The medium was then aspirated 
carefully, and the cells were switched to DMEM medium consisting 
of required concentration of API without disturbing the tissue. The 
tissue was incubated further for 24 h. The supernatant was 
aspirated, and the tissue was lysed using 250 µl of lysis buffer in 
each well. Lysis of the cells was facilitated by incubating the plates 
for 30 min at 37 °C. Later, appropriate tissue lysates were collected 
and pooled together in a microcentrifuge tube, centrifuged at 1000 
rpm for 3 min. The pellet was discarded and the supernatant was 
collected in a separate sterile microcentrifuge tube. To this 
acetonitrile was added in order to precipitate the proteins present. 
The extract was vertex and then centrifuged at 8000 rpm for 10 min. 
The pellet was discarded, and the supernatant was filtered through 
0.22 µ Millipore membrane filter and used for further analysis on 
LC-MS/MS.  
Blank was prepared in a similar fashion without spiking of the drug. 
LC-MS/MS analysis 
HPLC system (Shimadzu prominence binary gradient system, 
Shimadzu Corporation, Japan) equipped with a binary pump (LC-
30AD), autosampler (SIL-30ACMP), a temperature controlled 
column compartment (CTO-30A) and photodiode array detector 
(SPD-M20A) was used. Chromatographic data was acquired using 
Lab solutions software. The analysis was done using Shim-pack XR 
ODS column (100 mm x 2 mm, 3 µ). The mobile phase comprised 
of-(A) water (pH 3.0 adjusted with formic acid) (B) acetonitrile, in 
a gradient mode. The gradient program is given in table 1. The 
flow rate was maintained at 0.5 ml/min; injection volume was 1 µl 
and the column temperature was maintained at 40 °C. Run time for 
the analysis was kept 8 min. The chromatograms were monitored 
at 225 nm. The structure elucidation of the metabolites was done 
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using triple quadrupole mass spectrometer LCMS-8040 equipped 
with electrospray ionization (ESI) source, operated in positive 
mode. 
Nitrogen gas was used at flow rates of 1.5 l/min for nebulization, 15 
l/min for heating and as a drying gas at 15 l/min. Argon was used 
heating gas as a collision gas. The collision energy was optimized 
and set to-30.0 V. Mass spectra were acquired over m/z range of 80-
700. Event time was off 0.08 seconds. 
 
Table 1: Gradient program used for the analysis 
Time A (%) B (%) 
0.01 60 40 
1.00 60 40 
3.00 0 100 
5.00 0 100 
5.50 60 40 
8.00 60 40 
 
Fig. 2: Images of the cells taken from inverted microscope (a) cells of the blank sample (b) cells spiked with drug, showing fine 
granulation in the nuclear region and expected stressed conditions as compared to the control 
 
RESULTS AND DISCUSSION 
As already mentioned, the main aim of the present study was to 
investigate the in vitro metabolic profile of ETD employing LC-
MS/MS technique. For this, two in vitro models were used, namely, 
normal human hepatic cell lines and chicken liver tissue.  
Though the metabolites of ETD have been studied in different types 
of samples including blood, urine, plasma etc. [19, 20] these two in 
vitro models were not used in the past. The desired drug 
concentration to be used and incubation time to be set for the 
experiment were initially optimized.  
Finally, the metabolites were produced by incubating the desired 
amount of drug with the liver cell lines and chicken liver tissue 
at optimized test conditions. The incubated extracts were 
analyzed on LC-MS/MS and their product ion scan spectra were 
acquired, interpreted, and tentative structures were proposed. 
The production scans of the metabolites are given in fig. 3, while 
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(c) m/z 290 
 
(d) m/z 302 
 
(e) m/z 304 
 
(f) m/z 330 
 
(g) m/z 463 
Fig. 3: (a–g): Product ion scans of etodolac and its metabolites 
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Table 2: Precursor ions and their respective product ion scan obtained from liquid chromatography-tandem mass spectrometry study 
Metabolites Precursor ions (m/z) Collision energy used product ion scan obtained (m/z) 
M1 244 -30 V 84, 100, 103, 115, 143, 162, 182 
M2 290 85,100, 113, 137,159, 208, 247, 249, 273 
M3 302 133, 155, 192, 226, 260, 284 
M4 304 132, 142, 160, 170, 188, 216, 244 
M5 330 81, 108, 122, 137,149, 171,187, 215,220, 258, 295 
M6 463  81, 243, 258, 327 
 
Table 3: The masses and possible chemical reactions of the identified metabolites of etodolac 
Masses of the metabolites (m/z) Mass difference w. r. t. t drug molecule (∆ m) Possible reactions 
244 -44 Decarboxylation (loss of CO2) 
290 +2 Hydrogenation (addition of two H) 
302 +14 Methylation (loss of H, addition of CH3) 
304 +16 Oxidation (addition of O) 
330 +42 N-acetylation (loss of H, addition of CH3CO) 
463 +175 Glucuronide conjugation (loss of H and addition of 
glucoronic acid) 
m/z: mass/charge value; ∆ m: mass difference; mass of Etodolac = m/z 288 
 
Six phase I and phase II metabolites were identified in the proposed 
study. The masses ([M+H]+) of the obtained metabolites and the 
possible chemical biotransformation reactions are mentioned in 
table 3. The masses (m/z) of the metabolites were found to be 244, 
290, 302, 304, 330 and 463. 
The possible biotransformations were predicted based on the mass 
difference of the metabolites with respect to the parent drug and the 
acquired product ion scan scan. There was a mass difference of 44 
units for the metabolite-M1 with mass 244 (C16H21NO). The nearest 
possible reaction therefore suggested was decarboxylation (loss of 
CO2 moiety). M1 produced the following ions with mass (m/z) as: 
182 (C13H12N·), 162 (C11H15N), 143 (C10H9N··), 115 (C8H5N··), 103 
(C6H14O), 100 (C6H12O··), 84 (C5H8O). From these, fragments with 
mass (m/z) 84,115 and 143 were same to that of ETD. Likewise, 
other chemical changes were also predicted; a mass gain of 2 unit for 
M2 (m/z 290-C17H23NO3) was described to be hydrogenation. M2 
gave the following fragments with mass (m/z) as: 273 (C17H22NO2·), 
249 (C15H23NO2), 247 (C15H21NO2), 208 (C13H21NO), 159 (C11H13N), 
137 (C9H15N), 113 (C7H15N), 100 (C6H12O··), 85 (C5H8O). From these, 
fragment with mass (m/z) 85 was same as that of the parent drug, 
while fragments with mass 100 and 137 were same as that of M1 
and M5 respectively. Also, fragment m/z 159 could be said to be 
similar to the fragment m/z 157 present in ETD on the basis of 2 
unit mass gain of M2 (hydrogenation), the same being reflected in 
the fragment m/z 159. A mass gain of 14 units for M3 (m/z 302-
C18H23NO3) was explained as methylation. M3 fragmented into ions 
with mass (m/z): 284 (C18H21NO2), 260 (C16H21NO2), 226 (C15H15N), 
192 (C12H17NO), 155 (C10H19N), 133 (C9H11N). From these, fragments 
with mass (m/z) 155 and 260 bear a close similarity with fragments 
of the parent drug; while fragment m/z 133 was same as that of M4. 
A mass gain of 16 unit for M4 (m/z 304-C17H21NO4) was proposed to 
be oxidation. M4 produced the following ions with mass (m/z): 244 
(C15H18NO2·), 216 (C13H14NO2·), 188 (C11H10NO2·), 170 (C11H8NO·), 160 
(C10H9NO), 142 (C10H8N·), 132 (C9H9N). From these, fragments with 
mass (m/z) 244, 216 and 188 showed the corresponding16 unit 
mass gain when compared with the fragments of the parent drug.  
A mass gain of 42 unit for M5 (m/z 330-C19H23NO4) was explained as 
N-acetylation. The fragments (m/z) obtained for M5 were: 295 
(C19H21NO2), 258 (C16H19NO2), 220 (C14H21NO), 215 (C14H17NO), 187 
(C12H13NO), 171 (C12H13N), 149 (C10H5N), 137 (C9H15N), 122 (C8H11N), 
108 (C8H12), 81 (C6H8). The fragment with mass m/z 258 was same as 
that of ETD while fragments with mass (m/z) 81, 187, 171 and 187 
were found to be similar with the other metabolites. M6 with a mass 
gain of 175 units was explicated as the glucuronide of dehydrogenated 
ETD (M6-m/z 463). M6 (C23H29NO9) fragmented into ions with mass 
(m/z) as: 327(C19H21NO4), 258 (C15H15NO3), 243 (C15H17NO2), 81 
(C6H8). The fragment with m/z 258 was same as that of ETD. 
These metabolites were so far not reported in the literature. The 
previous studies were only successful in finding the mono-
hydroxylated metabolites of the drug and their acyl-
glucuronides [3, 19-23]. These were assumed to be ETD 
metabolites on comparison with the blank (incubation of the cell 
lines and the chicken liver tissue without ETD) and also on the 
basis of the justification given above for the fragmentation 
pattern of the metabolites. 
It was also found that two of the metabolites, with masses-m/z 244 
and m/z 304 were reported as the degradation products of ETD in 
one of the study [26].  
Based on all the above information, the tentative structures of the 
investigated metabolites were postulated (fig. 4) and a tentative 
scheme of biotransformation of ETD in the two studied in vitro 
models was presented in fig. 5.  
 
 
Fig. 4: Tentative postulated structures of the in vitro phase I and 
phase II metabolites of etodolac 
 
Besides characterizing the metabolites of ETD, another objective of 
the proposed research work was also to perform a comparative 
study of the metabolic profile of the drug obtained in the two 
selected in vitro models. Since the same metabolites were formed in 
both the in vitro test models, it could be indicated that the drug 
underwent a similar kind of biotransformation in both the cases. 
Hence, it could be stated that both, human hepatic cell lines and 
chicken liver tissue are equally effective in vitro models for studying 
the in vitro metabolic profile of ETD. 
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Fig. 5: Tentative scheme of biotransformation of etodolac 
 
CONCLUSION 
Thus, in the proposed study, six phase I and phase II metabolites 
of ETD were successfully detected and identified employing LC-
MS/MS technique, in two in vitro models, namely, human hepatic 
cell lines and chicken liver tissue. Both the in vitro models were 
found to be equally effective in producing the metabolites and 
produced the same metabolites. The masses ([M+H]+) of these 
metabolites were found to be-m/z 244, m/z 290, m/z 302, m/z 
304, m/z 330 and m/z 463. The main chemical changes observed 
in the drug molecule during the pr°Cess of metabolism included 
oxidation, N-acetylation, hydrogenation, decarboxylation, 
methylation and glucuronide conjugation. Production scans were 
acquired and interpreted for the detected metabolites. Based on 
the interpretations and the remaining information, the tentative 
structures of the investigated metabolites and a biotrans-
formation scheme of ETD in the two studied in vitro models were 
postulated.  
ACKNOWLEDGEMENT 
The authors are obliged to Dr. Siddhivinayak Barve, the Director of 
Kelkar Scientific Research Centre (Mumbai, India) for allowing us to 
carry out the sample preparation part of the study at their research 
center. We highly appreciate the efforts put in by Dr. Kshitij 
Satardekar for rendering his help for this purpose. The authors are 
grateful to Shimadzu Analytical India Pvt. Ltd (Mumbai, India) for letting 
the LC-MS/MS study be carried out in their lab.  
The authors are thankful to Guru Nanak Institute of Research and 
Development, Guru Nanak Khalsa College, Matunga, Mumbai, India 
for providing all the research related facilities, required in 
accomplishing the present research work. 
One of the authors is also grateful to Department of Science and 
Technology (DST), India for providing the INSPIRE fellowship. 
CONFLICT OF INTERESTS  
Declare none 
REFERENCES 
1. Patel A, Shah B. RP-HPLC method development and validation 
using the factorial design for simultaneous estimation of 
thi°Colchicoside and etodolac with forced degradation studies. 
J Pharma Sci Biosci Res 2014;4:374-82. 
2. Pandey R, Patil PO, Bari SB, Dhumal DM. Simultaneous 
estimation of etodolac and thi°Colchicoside in bulk and in 
tablet formulation by UV spectrophotometry. Chem Ind Chem 
Eng Q 2014;20:9-17. 
3. Dirk BS, Gottfried B. Isolation of an unknown metabolite of the 
non-steroidal anti-inflammatory drug Etodolac and its 
identification as 5-hydroxy Etodolac. J Pharm Biomed Anal 
2001;25:977-84. 
4. Devarakonda RK, Ulrich K. Extrahepatic metabolism of drugs in 
humans. Clin Pharmacokinet 1994;26:144-60. 
5. Schonborn LJ. The role of the liver in drug metabolism. 
Anaesthesia Tutorail Week 2010;179:1-6. 
6. Prakash C, Shaffer CL, Nedderman A. Analytical strategies for 
identifying drug metabolites. Mass Spectrom Rev 
2007;26:340-69. 
7. Brandon EF, Raap CD, Meijeram I, Benjnen JH, Schellens JH. An 
update on in vitro test methods in human hepatic drug 
biotransformation research: pros and cons. Toxicol Appl 
Pharmacol 2003;189:233-46. 
8. Fasinu P, Bouic PJ, Rosenkranz B. Liver based in vitro 
technologies for drug biotransformation studies-a review. Curr 
Drug Metab 2012;13:215-24. 
9. Becker SU, Blaschke G. Evaluation of the stereoselective 
metabolism of the chiral analgesic drug Etodolac by high-
performance liquid chromatography. J Chromatogr 
1993;621:199-207. 
10. Jamali F, Mehvar R, Lemko C, Eradiri O. Application of a 
stereospecific high-performance liquid chromatography assay 
to a pharmacokinetic study of Etodolac enantiomers in 
humans. J Pharm Sci 1988;77:693-6. 
11. Wright MR, Jamali F. Limited extent of stere°Chemical 
conversion of chiral non-steroidal anti-inflammatory drugs 
induced by derivatization methods employing ethyl 
chloroformate. J Chromatogr 1993;616:59-65. 
12. Turcant A, Premel-Cabic A, Cailleux A, Allian P. Toxicological 
screening of drugs by microbore high-performance liquid 
chromatography with photodiode-array detection and 
ultraviolet spectral library searches. Clin Chem 
1991;37:1210-5. 
13. Lapicque F, Netter P, Bannwarth B, Trechot P, Gillet P, Lambert 
H, et al. Identification and simultaneous determination of non-
steroidal anti-inflammatory drugs using high-performance 
liquid chromatography. J Chromatogr Biomed Appl 
1989;496:301-20. 
14. Pirkle WH, Murray PG. The separation of the enantiomers of a 
variety of non-steroidal anti-inflammatory drugs (NSAIDs) as 
their anilide derivatives using a chiral stationary phase. J Liq 
Chromatogr 1990;13:2123-34. 
15. Singh NN, Jamali F, Pasutto AS, Coutts RT, Russel AS. 
Stereoselective gas chromatographic analysis of Etodolac 
enantiomers in human plasma and urine. J Chromatogr 
1988;382:331-7. 
16. Schmutz A, Thomann W. Assessment of the impact of 
physic°Chemical drug properties on monitoring drug levels by 
micellar electrokinetic capillary chromatography with direct 
serum injection. Electrophoresis 1994;15:1295-303. 
17. Mayer S, Schurg V. Enantiomeric separation by electro 
chromatography in open tubular columns coated with Chiral-
DEX. J Liq Chromatogr 1993;16:915-31. 
18. Giachetti C, Assandri A, Zanolo G, Brembila E. Gas 
chromatography-mass spectrometry determination of Etodolac 
in human plasma following single epicutaneous administration. 
J Chromatogr Biomed Appl 1994;8:180-3. 
19. Dirk BS, Chankvetadze B, Blaschke G, Claudia D, Salvatore F. 
Separation and identification of etodolac and its urinary phase I 
metabolites using capillary electro chromatography and on-line 
capillary electro chromatography–electrospray ionization mass 
spectrometry coupling. J Chromatogr A 2000;887:393-407. 
20. Mohammed R, Abyazani K, Esaw B. Etodolac in equine urine 
and serum: Determination by high-performance liquid 
chromatography with ultraviolet detection, confirmation, and 
metabolite identification by atmospheric pressure ionization 
mass spectrometry. J Anal Toxicol 1999;23:200-9. 
21. Ferdinandi ES, Sehgal SN, Demerson CA, Dubuc J, Zilbert J, 
Dvornik D, et al. Disposition and biotransformation of 14C-
etodolac in man. Xenobiotica 1986;16:153-66. 
22. Berendes U, Blaschke G. Simultaneous determination of the 
phase II metabolites of the non-steroidal anti-inflammatory 
drug Etodolac in human urine. Enantiomer 1996;1:415-22. 
23. Ferdinandi ES, C°Chran D, Gedamke R. Identification of the 
Eodolac metabolite, 4-ureidoetodolac, in mouse, rat, dog, and 
man. Drug Metab Dispos 1987;15:921-4. 
Saxena et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 7, 373-379 
 
379 
24. Suchanova B, Kostiainen R, Ketola R. Characterization of the in 
vitro metabolic profile of amlodipine in the rat using liquid 
chromatography-mass spectrometry. J Pharm Sci 2008;33:91-9. 
25. Suchanova B, Sispera L, Wsol V. Liquid chromatography-
tandem mass spectrometry in the chiral study of Amlodipine 
biotransformation in rat hepat°Cytes. Anal Chim Acta 
2006;573:273-83. 
26. Saxena D, Damale S, Datar A, Bhandarkar D, Raju S, Rane S, et 
al. Characterization of products formed by forced degradation 
of Etodolac by LC-MS/MS. Presented ASMS 2015;15:1-7. 
 
